编号：2022-018 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-019 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □新闻发布会 \n□现场参观 \n□√其他（电话、线上会议） | □特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□路演活动 | | 参与单位名称 | | 信诚基金、泰信基金、浦银安盛基金、银河基金、建信基金、银华基金、 华夏久盈基金、申万菱信基金、华安证券、开源证券、民生证券、山西证券 | | | | | | 时间 | 2022 年 7 月 ...

编号：2022-020 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □√分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活 | □新闻发布会 | □路演活动 | | 动类别 | □现场参观 | | | | □√其他（电话、线上会议） | | | | | 中国人保、中信资管、中信保诚、中信期货、 ...

Group 1: Company Overview - Guizhou Xintian Pharmaceutical Co., Ltd. is listed under stock code 002873 and bond code 128091 [1] - The investor relations activity took place on November 10, 2022, in Shanghai [2] Group 2: Market Strategy - The company aims to ensure the growth of its leading products through clinical efficacy-driven marketing strategies [2][3] - Key strategies include optimizing marketing structure, enhancing brand promotion, and expanding market channels, particularly in lower-tier markets [3][4] Group 3: Research and Development Plans - The company focuses on two main areas: deepening expertise in gynecology and monitoring long-term market value [3] - Plans to increase R&D budget significantly in the coming year, with ongoing projects in innovative Chinese medicine, formula granules, and classic prescriptions [3][4] - The company has completed clinical trials for three innovative drugs and plans to apply for market approval in 2023 [3] Group 4: Production and Cost Management - The company has implemented smart manufacturing solutions to reduce production and labor costs, aiming for an annual output value exceeding 3 billion yuan [5] - New intelligent production lines and warehouses are expected to enhance efficiency and cost control [5] Group 5: Employee Incentives - The company plans to continue stock incentive programs for core positions to align employee growth with corporate development [5] - Emphasis on talent acquisition and internal performance evaluation to foster a motivated workforce [5]

Group 1: Company Performance - In the first half of 2022, the company achieved revenue of 525 million CNY, a year-on-year increase of 15.53% [3] - Net profit reached 57 million CNY, reflecting a year-on-year growth of 22.65% [3] - The company maintained operational stability despite challenges posed by the pandemic [3] Group 2: Strategic Response to Pandemic - The company adjusted inventory levels in anticipation of potential pandemic impacts, ensuring sufficient stock to meet demand [2] - Logistics channels were prioritized, with green transport corridors established to facilitate timely distribution [2] - Production schedules were adapted to quickly restore inventory levels during the pandemic [2] Group 3: Future Growth Strategy - The company is focused on a five-year strategic plan, with 2022-2023 being a critical overlap period for its second "three-year plan" [3] - Emphasis on sustainable growth through optimizing existing business and exploring new market opportunities [4] - The company aims to leverage its established product lines and market presence to achieve its "three-year doubling" business goal [4] Group 4: Marketing and Sales Development - The marketing team has been professionalized, with a focus on regional recruitment and specialized training [5] - The company has established long-term relationships with over 1,400 hospitals and 85,000 pharmacies nationwide [5] - The OTC product coverage includes over 800 chain pharmacies, enhancing market penetration [5] Group 5: Product Development and Innovation - The company is advancing three new drug applications, with expectations to submit for market approval in 2023 [4] - The "He Yan" brand, particularly the He Yan Kun Tai capsule, is positioned as a key product in the OTC market [6] - Marketing efforts for the He Yan brand include targeted advertising and promotional activities across various platforms [6]

编号：2022-022 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------|-------------------|-----------------------| | 投资者关系活 \n动类别 | □现场参观 \n□√其他（电话、线上会议） | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | | | | | | 人保养老 | 中信建投基金 | 中信期货 | 民生信托 中再资产 | | | | 华夏基金 | | 长城基金 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥344,696,330.89, representing an increase of 18.36% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥47,439,961.79, up 12.69% year-on-year, while the net profit excluding non-recurring gains and losses was ¥46,140,566.11, an increase of 16.56%[5]. - The net profit for the third quarter of 2022 was CNY 104,887,601.16, an increase of 18% compared to CNY 88,933,462.49 in the same period last year[20]. - Operating income for the third quarter reached CNY 116,780,742.51, up from CNY 101,463,975.16, reflecting a growth of approximately 15.5% year-over-year[19]. - The total revenue from sales of goods and services was CNY 823,211,488.02, up from CNY 730,647,546.59, indicating a growth of approximately 12.6%[22]. Earnings Per Share - The basic earnings per share (EPS) for the period was ¥0.2863, reflecting an 8.53% increase year-on-year, while diluted EPS was ¥0.2672, up 7.14%[5]. - The basic earnings per share increased to CNY 0.6332 from CNY 0.5519, representing a growth of about 14.7%[20]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,644,701,803.91, a 7.89% increase from the end of the previous year[5]. - As of September 30, 2022, total assets were CNY 1,644,701,803.91, up from CNY 1,524,426,501.68 at the beginning of the year, indicating a growth of 7.9%[17]. - The total liabilities as of September 30, 2022, were CNY 634,030,033.19, slightly up from CNY 633,983,091.90 at the beginning of the year[17]. - The company's equity attributable to shareholders reached CNY 1,010,671,770.72, an increase from CNY 890,443,409.78, reflecting a growth of 13.5%[17]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥62,907,793.14, showing a decrease of 35.60% compared to the previous year[10]. - The cash flow from operating activities generated a net amount of CNY 62,907,793.14, down from CNY 97,683,353.15, a decrease of about 35.5%[23]. - The company reported a cash and cash equivalents balance of CNY 89,909,959.56 at the end of the period, compared to CNY 98,284,359.97 at the end of the previous year, reflecting a decrease of approximately 4.5%[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,434[12]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 34.56% of the shares, with 33,821,441 shares pledged[12]. Borrowings and Investments - The company reported a significant increase in long-term borrowings, which rose by 399.37% to ¥25,000,000.00, attributed to new borrowings during the period[10]. - The short-term borrowings decreased to CNY 257,000,000.00 from CNY 268,342,558.34, a reduction of 4.9%[17]. - The company experienced a net cash outflow from investing activities of CNY 24,225,800.33, an improvement from a net outflow of CNY 198,550,274.06 in the previous year[23]. - The financing activities resulted in a net cash outflow of CNY 21,250,130.68, compared to a net outflow of CNY 130,936,122.11 in the same period last year[23]. Operating Costs and Expenses - The total operating revenue for the third quarter of 2022 reached CNY 869,234,233.67, an increase of 16.6% compared to CNY 745,264,628.80 in the same period last year[18]. - The total operating costs for the same period amounted to CNY 749,807,302.84, reflecting a rise of 16.3% from CNY 644,773,028.12 year-on-year[18]. - The total operating expenses rose to CNY 428,144,471.00, compared to CNY 366,976,813.99, an increase of approximately 16.6%[19]. - Research and development expenses increased to CNY 12,571,577.53, compared to CNY 11,714,744.33, marking a rise of about 7.3%[19]. Government Subsidies - The company received government subsidies amounting to ¥1,724,872.07 during the reporting period, contributing to its financial performance[7].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥524,537,902.78, representing a 15.53% increase compared to ¥454,031,233.06 in the same period last year[23]. - The net profit attributable to shareholders was ¥57,447,639.37, up 22.65% from ¥46,837,320.12 in the previous year[23]. - Basic earnings per share increased by 18.48% to ¥0.3469, compared to ¥0.2928 in the previous year[23]. - The company reported a net profit excluding non-recurring gains and losses of ¥55,472,739.77, a 19.06% increase from ¥46,590,801.43 in the same period last year[23]. - The company achieved a revenue of ¥524,537,902.78, representing a year-on-year increase of 15.53% compared to ¥454,031,233.06 in the previous year[53]. - The company's main business revenue reached ¥524.1 million, representing a year-on-year increase of 15.55%[55]. - The net profit for the first half of 2022 was CNY 67,436,924.64, representing a 22.1% increase from CNY 55,092,402.91 in the previous year[168]. - The total comprehensive income for the first half of 2022 was CNY 68,806,549.84, compared to CNY 59,299,116.77 in the first half of 2021, indicating a growth of 16.4%[173]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,621,253,562.39, a 6.35% increase from ¥1,524,426,501.68 at the end of the previous year[23]. - The company's total assets reached CNY 1,614,133,879.25, compared to CNY 1,529,630,827.36 at the beginning of the year, reflecting a growth of 5.5%[164]. - The total liabilities increased to CNY 653,020,092.21, up from CNY 644,189,946.00, indicating a rise of 1.3%[165]. - The company's asset-liability ratio stands at 41.11%, a slight decrease of 0.48% from the previous year[156]. Cash Flow - The net cash flow from operating activities decreased by 26.40% to ¥43,965,639.45, down from ¥59,736,164.46 in the same period last year[23]. - The company's cash and cash equivalents increased by 489.41%, reaching ¥55,165,108.36, mainly due to reduced bank loan repayments and increased bank borrowings[53]. - The ending balance of cash and cash equivalents was ¥85,559,440.63, compared to ¥234,174,509.64 at the end of the first half of 2021, reflecting a decrease of 63.4%[178]. - The total cash outflow for operating activities was ¥504,632,815.44, which increased by 29.0% from ¥391,065,369.54 in the previous year[177]. Research and Development - The company has completed clinical phase III trials for three new traditional Chinese medicine products, including Longcen Pelvic Comfort Granules[36]. - The company has a strategic focus on expanding its market presence and enhancing its product portfolio through continuous research and development[36]. - The company's R&D investment increased to ¥13,972,036.81, up 17.51% from ¥11,889,702.71 in the previous year, reflecting a growing commitment to innovation[53]. - Research and development expenses for the first half of 2022 were CNY 12,384,704.15, a decrease of 14.7% compared to CNY 14,520,861.28 in the same period of 2021[172]. Market and Product Development - The company has a focus on gynecological and urological medications, with products like Ningpitai Capsule and Kucan Gel being unique in the domestic market[33][34]. - The leading product, Kuntai Capsule, is a national essential drug and has ranked 2nd in the gynecology medication field in the 2020 and 2021 Clinical Value Chinese Medicine Brand List[32]. - The company has established a stable supply chain for raw materials, leveraging the rich medicinal resources available in Guizhou province, which accounts for 89.81% of the 363 key varieties surveyed nationwide[51]. - The company is focused on expanding its market reach, with its products covering over 11,500 hospitals and 85,000 retail outlets nationwide[50]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities, ensuring compliance with environmental regulations[95]. - The company emphasizes social responsibility by protecting investor rights, enhancing employee welfare, and engaging in community service[104]. - The company has introduced advanced energy-saving and environmental protection equipment to improve fuel utilization and reduce carbon emissions[103]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. Shareholder and Equity Information - The total number of shares before the change was 164,048,027, with a total after the change of 165,721,702, reflecting an increase of 1,673,675 shares[132]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 36.55% of the shares, totaling 60,576,547 shares, with 33,821,441 shares pledged[135]. - The company has not disclosed any significant impacts on financial metrics such as basic and diluted earnings per share due to the share changes[134]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[139].

Group 1: Event Details - The event is the "2021 Annual Performance Presentation and Investor Reception Day" scheduled for May 13, 2022, from 09:30 to 11:30 [1] - The event is organized by the Guizhou Securities Regulatory Bureau, Guizhou Securities Association, and Shenzhen Panorama Network Co., Ltd. [1] - The event will be held on the "Panorama Roadshow" platform [1] Group 2: Company Participation - Representatives from the company include Chairman and General Manager Dong Dalun, Director and Deputy General Manager Wang Jinhua, Secretary of the Board and Deputy General Manager Wang Guangping, and Chief Financial Officer Zeng Zhihui [1] - The company aims to enhance communication with investors and improve investor relations management [1] Group 3: Investor Engagement - The company is collecting questions from investors in advance to address common concerns during the event [1] - Investors can submit their questions via a dedicated webpage [1] - The company encourages active participation from investors [1]

Financial Performance - The company's operating revenue for Q1 2022 was ¥249,216,213.05, representing a 16.10% increase compared to ¥214,656,599.98 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was ¥30,879,340.57, up 21.73% from ¥25,366,384.98 year-on-year[3] - Basic earnings per share increased by 18.08% to ¥0.1868, compared to ¥0.1582 in the same period last year[3] - The operating profit for the first quarter was CNY 34,639,863.10, up from CNY 30,472,241.92, reflecting a growth of 7.1% year-over-year[18] - The total comprehensive income for the first quarter was CNY 30,879,340.57, compared to CNY 25,366,384.98, marking an increase of 21.5%[18] Cash Flow - The net cash flow from operating activities decreased by 77.96% to ¥3,695,741.81, down from ¥16,766,677.68 in the previous year[6] - The cash flow from investment activities for Q1 2022 was ¥31,179,154.70, a significant recovery from -¥65,463,297.81 in the previous year[6] - The cash and cash equivalents at the end of the period amounted to CNY 144,358,114.14, compared to CNY 226,589,843.63 at the end of the previous year, a decrease of 36.3%[21] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,588,465,962.04, a 4.20% increase from ¥1,524,426,501.68 at the end of the previous year[3] - The total liabilities increased slightly to RMB 644,546,790.79 from RMB 633,983,091.90 at the beginning of the year[14] - The company's total equity attributable to shareholders increased by 6.01% to ¥943,919,171.25 from ¥890,443,409.78 at the end of the previous year[3] Research and Development - Research and development expenses surged by 178.79% to ¥3,589,480.60, compared to ¥1,287,534.50 in the previous year[6] - Research and development expenses increased significantly to RMB 3,589,480.60, compared to RMB 1,287,534.50 in the same quarter of the previous year, reflecting a growth of 179.3%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,944[8] - The company raised CNY 83,000,000.00 through borrowings, significantly higher than CNY 13,000,000.00 in the previous year, indicating a strategic move to enhance liquidity[21] Operating Costs - The total operating costs for the first quarter of 2022 were RMB 214,995,242.32, up 17.0% from RMB 183,991,577.13 in the previous year[16] - Accounts receivable stood at RMB 218,276,635.91, showing a slight decrease from RMB 222,775,435.76 at the beginning of the year[12] - Inventory levels increased to RMB 154,519,844.54 from RMB 118,770,773.96, indicating a growth of 30.2%[13] - The short-term borrowings rose to RMB 308,000,000.00 from RMB 268,342,558.34, reflecting a growth of 14.8%[13] Government Subsidies and Tax - The company received government subsidies amounting to ¥1,364,741.35, an increase of 78.13% from ¥766,142.44 in the previous year[6] - The company incurred a total tax expense of CNY 3,754,291.98, down from CNY 4,916,577.28, a reduction of 23.6% year-over-year[18]